- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 14, 2023
Highlights
- Market Cap
- $9.26B
- Enterprise Value
- $8.82B
- EPS (TTM)
- -$3.24
- EBITDA (TTM)
- -$297.75M
- Year Range
- $34.34 - $133.16
- Target Price
- $109.44
- ROA (TTM)
- -15.50%
- ROE (TTM)
- -15.97%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
APGE Performance Chart
Apogee Therapeutics Inc. Common Stock (APGE) is up 76.1% since the beginning of the year. At $133 per share, APGE is currently trading at its 52-week high.
Loading charts...
Returns By Period
Apogee Therapeutics Inc. Common Stock (APGE) has returned 76.05% so far this year and 221.35% over the past 12 months.
Apogee Therapeutics Inc. Common Stock
- 1D
- 0.25%
- 1M
- 63.73%
- YTD
- 76.05%
- 6M
- 71.90%
- 1Y
- 221.35%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
APGE Monthly Returns History
Based on dividend-adjusted daily data since Jul 14, 2023, APGE's average daily return is +0.34%, while the average monthly return is +7.41%. At this rate, an investment would double in approximately 0.8 years.
Historically, 56% of months were positive and 44% were negative. The best month was Mar 2024 with a return of +90.8%, while the worst month was Apr 2024 at -24.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 3 months.
On a daily basis, APGE closed higher 51% of trading days. The best single day was Jun 22, 2026 with a return of +46.7%, while the worst single day was Jul 7, 2025 at -17.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -13.21% | 6.85% | 20.24% | -1.52% | -0.90% | 61.77% | 76.05% | ||||||
| 2025 | -8.70% | -23.98% | 18.83% | 5.06% | -6.65% | 18.53% | -11.90% | -4.94% | 9.24% | 42.44% | 27.18% | 4.88% | 66.62% |
| 2024 | 19.90% | 3.94% | 90.84% | -24.30% | -9.26% | -13.78% | 23.76% | 5.07% | 14.79% | -11.41% | -13.24% | 0.33% | 62.13% |
| 2023 | -0.47% | 7.20% | -7.15% | -19.34% | 13.56% | 43.21% | 29.95% |
Benchmark Metrics
Apogee Therapeutics Inc. Common Stock has an annualized alpha of 90.80%, beta of 1.24, and R2 of 0.07 versus S&P 500 Index. Calculated based on daily prices since July 14, 2023.
- This stock captured 265.96% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -40.14%) - a profile typical of hedging or uncorrelated assets.
- R2 of 0.07 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 90.80%
- Beta
- 1.24
- R²
- 0.07
- Upside Capture
- 265.96%
- Downside Capture
- -40.14%
Return for Risk
Risk / Return Rank
APGE ranks 95 for risk / return — in the top 95% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Apogee Therapeutics Inc. Common Stock (APGE) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| APGE | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.21 | ||
| Sortino ratioReturn per unit of downside risk | +1.64 | ||
| Omega ratioGain probability vs. loss probability | 1.54 | 1.32 | +0.22 |
| Calmar ratioReturn relative to maximum drawdown | 8.26 | 2.46 | +5.80 |
| Martin ratioReturn relative to average drawdown | 17.15 | 10.92 | +6.23 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Apogee Therapeutics Inc. Common Stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Apogee Therapeutics Inc. Common Stock was 58.75%, occurring on Apr 8, 2025. Recovery took 160 trading sessions.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -58.75%Apr 2025 | 1y 25d | 7mo 21d | 1y 8moMar 2024 - Nov 2025 |
2023 bear market2023 | -39.30%Oct 2023 | 1mo 21d | 1mo 25d | 3mo 16dSep 2023 - Dec 2023 |
2026 bear market2026 | -24.63%Feb 2026 | 21d | 1mo 24d | 2mo 15dJan 2026 - Mar 2026 |
2026 correction2026 | -15.67%May 2026 | 1mo 7d | 26d | 2mo 3dApr 2026 - Jun 2026 |
2024 correction2024 | -11.30%Jan 2024 | 9d | 5d | 14dDec 2023 - Jan 2024 |
Drawdown Indicators
| APGE | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -58.75% | -56.78% | -1.97% |
Max Drawdown (1Y)Largest decline over 1 year | -26.99% | -9.10% | -17.89% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | 0.00% | -3.21% | +3.21% |
Average DrawdownAverage peak-to-trough decline | -24.11% | -10.71% | -13.40% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.97% | 2.04% | +10.93% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Apogee Therapeutics Inc. Common Stock over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Apogee Therapeutics Inc. Common Stock is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for APGE in comparison with other companies in the Biotechnology industry. Currently, APGE has a P/B value of 7.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with APGE
Add Apogee Therapeutics Inc. Common Stock to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with APGE